Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
K36 Therapeutics Inc. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are being reviewed by 2 distinct examiners, providing the company with multiple individual perspectives on its current applications. However, both actions are situated within 1 distinct art unit, which indicates a concentrated technical focus for the portfolio. The busiest examiner, REDWOOD, CHRISTOPHER EVAN, is currently handling 1 pending office action, representing 1 of the 2 pending office actions total.
The fact that 2 pending office actions are being processed by 2 distinct examiners suggests a distributed approach to prosecution within the Biotechnology & Pharmaceuticals sector. Despite this, the 1 distinct art unit involved means that both examiners likely report to the same supervisory structure. Because the busiest examiner manages 1 pending office action, the workload is evenly split, ensuring that no single examiner has a majority share of the company's current pending matters within that art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18867118 | PIPERIDINYL-METHYLPURINE PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS | REDWOOD, CHRISTOPHER EVAN | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18867118 | PIPERIDINYL-METHYLPURINE PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS | REDWOOD, CHRISTOPHER EVAN | — | §102§103 | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18948783 | DEUTERIUM-ENRICHED PIPERIDINYL-METHYL-PURINE AMINE SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | SEAMAN, D MARGARET M | 1625 | §103§112DP | Non-Final OA | — | Pending | Nov 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialK36 Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Christopher Evan Redwood has the most, with 1 of K36 Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
